Maintenance therapy with rucaparib (Rubraca) maintained disease control and was well tolerated in patients with platinum-sensitive, advanced BRCA1/2- or PALB2-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial presented at the 2019 AACR Annual Meeting.
Of 19 evaluable patients who were treated with the PARP inhibitor, results showed that the median progression-free survival (PFS) was 9.1 months at a median potential follow-up of 257 days, and the median overall survival was not reached at a median potential follow-up of 244 days. Read more . . .